• 한국임상수의학회지
• /
• 제16권2호
• /
• pp.389-396
• /
• 1999

Pregnant rats were treated at various stages of gestation with prostaglandin analogue, cloprostenol alone or concomitant with HCG to study effects on termination of gestation and plasma estrogen and progesterone. Cloprostenol (90 or 180 mg/kg) was administered alone on 1~3, 4~6, 7~9, 9~11 or 11~13 consecutive days of gestation twice a day and in combination with HCG (50 or 100 IU/day) on days of 1~3 or 7~9 once a day. Rats were autopsied on day 21 of gestation or at 6, 12 or 24 hours after treatment on day 6 or 9, respectively. Cloprostenol was found to be nearly 100% effective in preventing implantation, destroying viable fetuses and causing preimplantation losses, but in early gestation, on days 1-3, there was little effect. And when cloprostenol administered concomitant with HCG, corpora lutea were significantly increased, implantation sites and viable fetuses significantly decreased, and pre-and post-implantation losses significantly increased in most cases. Plasma concentrations of estradiol and progesterone were significantly decreased by administering cloprostenol, and estradiol concentration significantly decreased but progesterone significantly increased by administering of cloprostenol concomitant with HCG. It is suggested that cloprostenol was more effective in terminating pregnancy than a combination of cloprostenol and HCG in the rat.

• 한국임상수의학회지
• /
• 제18권1호
• /
• pp.48-54
• /
• 2001

The effects of PMSG and/or prostaglandin analogue, cloprostenol, on the prevention of implantation, termination of pregnancy, concentration of plasma progesterone, and Na and K contents of the plasma and uterine fluid were studied in pregnant rats. PMSG 50 or 100 IU concomitant with cloprostenol 90 or 180 mg were administered once on day 3 or 9 of gestation. Rats were autopsied on days 8, 10 or 21 gestation. A single administration of PMSG resulted in increasing the number of corpora lutea, preventing implantation and terminating pregnancy. A single administration of cloprostenol had no effect on the prevention of implantation and termination of pregnancy but was able to induce the termination of pregnancy administering at large doses on day 9. A single administration of PMSG concomitant with cloprostenol ws found to be very increased the number of corpora lutea and to be 100% effective in preventing implantation and to be nearly 100% effective in terminating pregnancy. It is uncommon that a single dose of PMSG 50 IU concomitant with cloprostenol 90 or 180 mg on day 9 was able to maintain the pregnancy at very low rates of 0.3∼5.3%. Concentration of plasma progesterone and Na and K contents of the plasma and uterine fluid were increased or decreased administering PMSG and/or cloprostenol, but had no effect on preventing implantation and terminating pregnancy.

• 한국임상수의학회지
• /
• 제20권2호
• /
• pp.212-219
• /
• 2003

The effect of GnRH and/or hCG on the implantation, pregnancy, and the concentration of plasma estradiol and progesterone were studied in pregnant rats. GnRH 50, or 100ug and/or hCG 50 or 100 IU were administered once on day 2 or 9 of gestation, respectively. Rats were autopsied on days 8 or 16. Administration of GnRH on day 2 did not induce the prevention of implantation and termination of pregnancy but was able to induce termination of pregnancy administering on day 9. Administration of hCG induced delayed implantation on day 2 and termination of pregnancy on day 2 and 9. Administration of GnRH concomitant with hCG had no effect on prevention of implantation on day 2 but induced termination of pregnancy with a very increased fetal resorption on day 2 and with a moderate increased fetal resorption on day 9. Administration of GnRH concomitant with hCG on day 2 induced more increased termination of pregnancy compared to injection of GnRH or HCG and opposite result was observed on day 9. Plasma estradiol and progesterone concentrations by administering GnRH and/or hCG had no effect on the termination of pregnancy the pregnant rats.

• 한국임상수의학회지
• /
• 제19권3호
• /
• pp.322-327
• /
• 2002

The effect of GnRH alone and concomitant with PMSG on the prevention of implantation. termination of pregnancy, and concentration of plasma progesterone were studied in pregnant rats. GnRH 50, 100 or 200 ug alone and concomitant with PMSG 25 or 50 IU were administered once on day 2 or 9 of gestation, respectively. Rats were autopsied on days 7 or 20. Administration of GnRH on day 2 did not result in the prevention of implantation and termination of pregnancy but resulted in termination of pregnancy administering on day 9. Administration of GnRM concomitant with PMSG on day 2 or 9 resulted in prevention of implantation and termination of pregnancy, but injection of GnRH 50 ug concomitant with PMSG 25 IU on day 9 had only one live fetus. Administration of GnRH alone and concomitant with PMSG on day 2 had no effect on the concentration of plasma progesterone determining on day 7. Administration of GnRH concomitant with PMSG on day 2 resulted in decrease of progesterone level determining on day 20 but GnRH alone was normal level. Administration of GnRH alone and concomitant with PMSG on day 9 resulted in decrease of the concentration of progesterone but was normal concentration administering GnRH 50 ug concomitant with PMSG 25 IU.

• 한국임상수의학회지
• /
• 제21권2호
• /
• pp.109-114
• /
• 2004

The effect of Human Menopausal Gonadotropin(hMG) on the implantation, pregnancy, and the concentration of plasma progesterone were studied in pregnant rats. HMG 75 or 150 IU were administered once on day 1, 2, 3, 4, 9, 12 or 14 of gestation, respectively. Rats were autopsied on day 7 or 18. A single dose of hMG prevented implantation and terminated pregnancy in all of the rats by injecting on either day 1 or day 2 and this abortifacient action was effective 82-98% of pregnant rats on day 3 or 4 and 14-20% on day 9 or 12. Administration of hMG had no effect on termination of pregnancy on day 14. Plasma progesterone concentration by injecting hMG on day 1, 2, 3 or 4 were very decreased.

• 한국보건간호학회지
• /
• 제3권1호
• /
• pp.38-60
• /
• 1989

The present analysis was undertaken to find out the relationships between birth weight & Apgar Score of newborn infant & maternal factors. The medical records of 1436 newborn infants who had been at the Korea University III Seoul from January. 1.1984. to December. 31. 1985, were examined. Measurements include weight and Apgar Score. As the possible factors influencing the birth weight & Apgar Score of newborn infant, 9 variables such as : mother's age, frequency ·of pregnancy, frequency of fullterm delivery, frequency. of premature, frequency of abortion, mother's hemoglobin level, complications during pregnancy gestational period and infant sex at birth were selected among the items recorded in the medical records of newborn infants and their mothers. The weight & Apgar Score of newborn infants were compared separately by sex with group percent of those variables. The results were summarized as follows: 1. All of those factors chosen are supposed to be influencing upon the birth weight and Apgar Score examined at birth indirectly through inducing early termination of pregnancy. 2. The most influencing variable of birth weight of newborn infants was gestation period. The most influencing variable of Apgar Score of infant newborn was gestation period. 3. The relationships of those influencing factors are more clear on the birth weights of newborn than on the Apgar Score. 4. More then half of low birth weight infants are turned out to be physiologically normal through the evaluation by Apgar Scoring. Conclusively, All of those factors chosen are supposed to be influencing upon the birth weight and apgar score examined at birth indirectly through inducing early termination of pregnancy.

• Journal of Genetic Medicine
• /
• 제2권2호
• /
• pp.49-51
• /
• 1998

Wolf-Hirschhorn syndrome (WHS) is caused by a deletion of the short arm on chromosome 4 and is characterized by multiple congenital abnormalities, growth and mental retardation. In this case report, we performed amniocentesis for the chromosome analysis on a 25-year-old pregnant woman at 16 weeks of gestation whom we suspected of Edward's syndrome by the triple test of maternal serum and ultrasonography. The result of analysis revealed a karyotype of the fetus with 46,XY,del(4)(p15) by trypsin Giemsa's banding technique. With the result, we were able to diagnose the fetus as having WHS. As such, after therapeutic termination of the pregnancy, we confirmed WHS through the sampling of tissue by both trypsin Giemsa's banding and fluorescence in situ hybridization (FISH) method. To determine the origin of the WHS, we further tested the karyotypes of the parents. As parental karyotypes were found to be normal, we determined the case of the fetal WHS to be de novo.

• Journal of Chest Surgery
• /
• 제33권6호
• /
• pp.502-506
• /
• 2000

Background: Anticoagulant therapy can be required during pregnancy with prosthetic heart valves. Warfarin and heparin provide real protection against thromboembolic phenomena, but they also carry serious risks for the fetus and the mother. In an attempt to identify the best treatment for pregnant women with cardiac valve prostheses who are receiving anticoagulant, we studied 19 pregnancies, the warfarin was discontinued and heparin was administered every 12 hours by subcutaneous injection in doses adjusted to keep the midinterval aPTT in the therapeutic range(at least 2-2.5 control) from the conception to the 12th week of gestation and oral antiocagulant was then administered until the middle of the third trimester in the therapeutic range(at least 2 INR), and heparin therapy was restared until delivery. Also in order to avoid an anticoagulant effect during delivery, it has been our practice to instruct women to either discontinue their heparin injections with the onset of labur or to stop heparin injections 12 hours prior to the elective induction of labour. Result: The outcome of 19 pregnancies managed with above protocol was spontaneous abortion in 3 cases, voluntary termination in 2 cases, premature delivery at 35 weeks in 1 case and delivery at full-term in 14 cases. There was no maternal morbidity and moratality and fetopathy. Conclusion: We conclude that in the second and third trimester of pregnancy, warfarin provide effective protection against thromboembolism, Oral antiocagulant therapy should be avoided in 2 weeks before delivery because of the risk of serious perinatal bleeding caused by the trauma of delivery to the anticoagulated fetus. However, the substitution of heparin at first trimester and 2 weeks before delivery reduce the incidence of complications.

• Tuberculosis and Respiratory Diseases
• /
• 제57권1호
• /
• pp.66-71
• /
• 2004

저자들은 임신중기에 대량객혈로 내원하여 안정, 산소공급, 폐혈관확장제, 치료적 유산 그리고 항응고제 사용 등으로 치료하였으나 결국 우심부전으로 사망한 원발성 폐고혈압 환자 1예를 경험하였다. 본 증례는 폐관류 및 환기스캔, 폐혈관조영술 등의 검사와 사망후 부검은 시행하지 못하였으나 현재까지의 검사결과에 의거 시 임신 중 대량객혈로 발현된 일차성 폐고혈압으로 사료되어, 이에 문헌고찰과 함께 보고하는 바이다.

• Journal of Yeungnam Medical Science
• /
• 제2권1호
• /
• pp.229-235
• /
• 1985

1983년 5월 28일 개원 이래 1985년 9월 30일까지 2년 4개월 동안 본 영남대학교 의과대학 부속영원 산부인과에 입원 가료한 바 있는 자궁외임신 88예를 대상으로 하여 임상적으로 조사, 관찰, 분석한 결과 다음과 같은 결론을 얻었다 1. 자궁외임신의 분만수에 대한 반도는 1 : 22.2였다. 2. 빈발연령은 30~34세가 38.6%로 가장 많았으며, 25~34세는 67%였다 3. 분만횟수와 임신중절 횟수가 증가할수록 자궁외임신의 빈도는 감소하는 경향을 보였다. 4. 기왕력은 골반염이 25%, 복강경 불임술이 13.7%였으며 반복 자궁외임신은 6.8%였다. 5. 주요증상은 하복부 동통이 85.2%, 질출혈이 56.8%였으여 Shock증상은 3.4%였다. 6. 입원 당시 혈색소치는 8gm% 이하인 경우가 6.8%, 10gm% 이하가 37.5%였으며 복강내 출혈은 1,000ml 이하가 53.4%였으며 2,000ml 이상이 22.8%였다. 7. 뇨 임신반응검사의 양성율은 파열군 (78%) 및 유산군 (63.3%)이 무상군 (54.5%)에 비해 높았으나 통계적인 의의는 없었다. 8. 더글라스씨와 천자의 양성율은 75.9%였다. 9. 임신주수별로는 6~9 주 사이가 48.9%로 가장 많았고 12주 이상이 15.9%였다. 10. 착상부위별로는 난관이 96.6%로서 그 중 팽대부가 60.2%, 협부 23.9%, 난관채부 9.1%, 간질부 3.4%였다. 11. 조사기간 동안 내원한 자궁외임신 88예중 사망한 예는 없었다.